Heron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Down 6.0% in October

Heron Therapeutics, Inc. (NASDAQ:HRTX) saw a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 28,810,000 shares, a decline of 6.0% from the October 15th total of 30,640,000 shares. Based on an average daily volume of 1,830,000 shares, the short-interest ratio is presently 15.7 days.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on HRTX shares. StockNews.com upgraded Heron Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, November 13th. Needham & Company LLC decreased their target price on shares of Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a report on Wednesday, November 13th.

Heron Therapeutics Stock Down 4.0 %

Shares of Heron Therapeutics stock opened at $1.19 on Monday. Heron Therapeutics has a 12 month low of $0.81 and a 12 month high of $3.93. The stock has a market cap of $181.00 million, a PE ratio of -6.61 and a beta of 1.81. The business has a fifty day simple moving average of $1.82 and a 200-day simple moving average of $2.51.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). The business had revenue of $32.81 million for the quarter, compared to analyst estimates of $36.40 million. During the same quarter in the previous year, the business posted ($0.17) earnings per share. Analysts expect that Heron Therapeutics will post -0.13 EPS for the current fiscal year.

Institutional Trading of Heron Therapeutics

Several institutional investors have recently made changes to their positions in the stock. nVerses Capital LLC acquired a new stake in shares of Heron Therapeutics during the 2nd quarter valued at $27,000. HB Wealth Management LLC purchased a new stake in shares of Heron Therapeutics during the second quarter worth $35,000. B. Riley Wealth Advisors Inc. acquired a new stake in Heron Therapeutics during the second quarter valued at $41,000. Sei Investments Co. purchased a new position in Heron Therapeutics in the second quarter valued at about $44,000. Finally, Valeo Financial Advisors LLC acquired a new position in Heron Therapeutics in the 2nd quarter worth about $45,000. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.